PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
An article by a News Reporter-Staff News Editor at Health and Medicine Business Daily
Read this article by Danielle Ternyila published in Targeted Oncology.
An article by a News Reporter-Staff News Editor at Immunotherapy Daily
Hormone therapies for advanced prostate cancer have greatly prolonged the lives of patients
Enzalutamide has previously been FDA-approved for treatment of metastatic castration-resistant prostate cancer (mCRCP) and non-metastatic castration-resistant prostate cancer (nmCRPC).
A new pilot study concludes that at-home urine tests could make prostate cancer diagnosis shorter, simpler, and possibly even more accurate.
After treatment, 65 percent of men in study had no signs of cancer after one year.
By Radiological Society of North America, December 2, 2019
The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the American Society of Clinical Oncology.
Some men are more likely to be diagnosed with prostate cancer depending on two factors, according to research presented at the 2019 National Cancer Research Institute Conference.